SYK Stock Analysis — Stryker Corporation
Sector: Healthcare
AI Verdict
Stryker trades at 18.9x next year's earnings with 80.4% EPS growth expected, making it cheap for the growth on offer if its entrenched hospital footprint delivers the rebound analysts see.
Competitive Moat
Stryker dominates in orthopedic implants and surgical equipment, benefiting from high switching costs as hospitals and surgeons standardize on its proprietary systems. Its defensibility comes from deep integration with hospital workflows and a broad patent portfolio protecting its medical devices.
Summary
Stryker's stock is at a technical extreme, with an RSI of 12.8 and a forward P/E of 18.9x despite analysts expecting 80.4% EPS growth next year.
Where It Stands
Shares are down -22.07% over the past year, RSI is deeply oversold at 12.8, and the forward P/E of 18.9x is below the healthcare sector median of 22x.
Key Metrics
- RSI: 12.8 — Oversold
- Trailing P/E: 34.1x
- Forward P/E: 18.9x
- PEG Ratio: 0.46
- Earnings Growth: +0.8%
- Revenue Growth: +0.1%
- Market Cap: $112.9B
- Dividend Yield: 0.01%
- 1-Year Return: -22.07%
- 52-Week High: $404.87
- 52-Week Low: $294.55
Analyst Consensus
28 Buy · 9 Hold · 0 Sell (37 analysts)
Bull Case
With analysts forecasting 80.4% EPS growth and the stock trading at just 18.9x forward earnings, you're paying a low price for a big earnings rebound if Stryker's hospital relationships hold.
Bear Case
If the P/E reverts to the sector median of 22x but earnings disappoint, the -22.07% one-year return and extreme RSI suggest further downside risk if sentiment doesn't reverse.
Catalyst to Watch
Watch for quarterly earnings updates—confirmation of the 80.4% EPS growth outlook could trigger a sharp bounce from oversold levels.